Accurate staging of Alzheimer's disease has historically required expensive, invasive brain imaging — a barrier that excludes most patients worldwide from precise diagnosis and prognosis. A blood-based staging system that reliably replicates PET scan results would fundamentally change who gets access to early detection, clinical trial enrollment, and emerging disease-modifying therapies.
Using data from two independent cohorts — the Swedish BioFINDER-2 study and the Knight Alzheimer Disease Research Center (ADRC), spanning nearly 2,500 participants from cognitively unimpaired adults through dementia stages — researchers developed a plasma-based biological staging model anchored on two specific tau biomarkers. The first, eMTBR-tau243, reflects endogenous cleavage of tau within the microtubule-binding region at residue 243, a structural site implicated in tau aggregation dynamics. The second, %p-tau217, captures the ratio of phosphorylated-to-unphosphorylated tau at threonine 217, which tracks amyloid-driven tau pathology. Together, the two-biomarker panel was validated against the revised Alzheimer's Association amyloid-tau PET staging criteria, with a subsample also confirmed against neuropathological data — providing unusually robust biological grounding.
This work is analytically significant for several reasons. Plasma %p-tau217 has rapidly emerged as one of the most accurate single blood biomarkers for amyloid and tau pathology, with prior studies achieving AUC values exceeding 0.90 for amyloid PET concordance. Adding eMTBR-tau243 — a marker less widely studied but increasingly recognized as reflecting tau fibril dynamics — may extend staging precision into earlier continuum stages where single-marker models begin to fail. The observational longitudinal design limits causal inference, and replication in more diverse, non-research clinical populations remains essential. Nonetheless, if this staging system translates to standard clinical laboratories, it could bring PET-equivalent diagnostic granularity to community neurology settings — a genuinely paradigm-shifting prospect for Alzheimer's care equity.